Nursing Elites

1. A client has a new prescription for Calcitonin-salmon for Osteoporosis. Which of the following tests should the nurse tell the client to expect before beginning this medication?

• A. Skin test for allergy to the medication
• B. ECG to rule out cardiac dysrhythmias
• C. Mantoux test to rule out exposure to tuberculosis
• D. Liver function tests to assess risk for medication toxicity

Correct answer: A

Rationale: Before starting Calcitonin-salmon, it is important to assess for any potential allergies as anaphylaxis can occur. A skin test is usually conducted to determine if the client is allergic to the medication. The nurse should also inquire about any previous allergies to fish, as Calcitonin-salmon is derived from salmon. Options B, C, and D are not necessary before initiating Calcitonin-salmon therapy. ECG is not directly related to this medication, Mantoux test is used to diagnose tuberculosis, and liver function tests are not specifically required before starting Calcitonin-salmon.

2. A client has a new prescription for Allopurinol. Which of the following instructions should be included by the healthcare provider?

• A. Take this medication at bedtime.
• B. Increase your fluid intake.
• C. Avoid foods high in calcium.
• D. Take this medication with meals.

Correct answer: B

Rationale: Allopurinol can increase the risk of kidney stones as a side effect. To prevent this adverse effect, it is essential for the client to increase their fluid intake. Adequate hydration can help in preventing the formation of kidney stones by keeping urine dilute and flushing out substances that can lead to stone formation.

3. When starting therapy with raloxifene, a client should monitor for which of the following adverse effects?

• A. Leg cramps
• B. Hot flashes
• C. Urinary frequency
• D. Hair loss

Correct answer: B

Rationale: The correct answer is B: Hot flashes. When initiating therapy with raloxifene, clients should be advised to monitor for hot flashes as they are a common adverse effect associated with this medication. Hot flashes are a well-known side effect of raloxifene due to its action on estrogen receptors. Leg cramps (Choice A), urinary frequency (Choice C), and hair loss (Choice D) are not typically associated with raloxifene therapy. Therefore, monitoring for hot flashes is crucial to manage and address this common side effect appropriately.

4. A healthcare professional is preparing to administer Pamidronate to a client who has bone pain related to cancer. Which of the following precautions should the healthcare professional take when administering pamidronate?

• A. Inspect the IV site for redness and irritation when changing the intravenous patch.
• B. Assess the IV site for thrombophlebitis frequently during administration.
• C. Instruct the client to sit upright or stand for 30 min following intravenous administration.
• D. Watch for manifestations of anaphylaxis for 20 min after intramuscular administration.

Correct answer: B

Rationale: Pamidronate is administered through intravenous (IV) infusion. As this medication can be irritating to veins, the healthcare professional should carefully assess the IV site for thrombophlebitis during administration to prevent potential complications. Choice A is incorrect as Pamidronate is not administered via intradermal patch. Choice C is incorrect as it does not relate to the administration of Pamidronate. Choice D is incorrect as Pamidronate is not administered intramuscularly.

5. A healthcare provider is reviewing the health history of a client who is starting therapy with tamoxifen. The healthcare provider should recognize that tamoxifen is contraindicated in which of the following clients?

• A. A client with a history of deep-vein thrombosis
• B. A client with a history of migraine headaches
• C. A client with a history of hypertension
• D. A client with a history of anemia

Correct answer: A

Rationale: Tamoxifen is contraindicated in clients with a history of thromboembolic events, such as deep-vein thrombosis, due to the increased risk of blood clots forming and leading to serious complications like pulmonary embolism. Clients with a history of deep-vein thrombosis are at a higher risk of recurrent thromboembolic events when taking tamoxifen, making it unsafe for such individuals. Choices B, C, and D are not contraindications for tamoxifen therapy, as migraine headaches, hypertension, and anemia do not directly interact with tamoxifen's mechanism of action or pose significant risks when used together.

Similar Questions